Barclays PLC Pro Qr Therapeutics N.V. Transaction History

Barclays PLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.56 - $1.0 $12,656 - $22,600	-22,600 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.9 - $8.39 $20,322 - $189,446	22,580 Added 112900.0%	22,600 $20,000
Q4 2021 Feb 14, 2022	SELL	$6.58 - $8.44 $19 - $25	-3 Reduced 13.04%	20 $0
Q3 2021 Nov 09, 2021	SELL	$5.16 - $8.47 $61 - $101	-12 Reduced 34.29%	23 $0
Q1 2021 May 13, 2021	SELL	$4.14 - $9.22 $13,053 - $29,070	-3,153 Reduced 98.9%	35 $0
Q4 2020 Feb 11, 2021	SELL	$3.58 - $4.85 $20,764 - $28,129	-5,800 Reduced 64.53%	3,188 $13,000
Q3 2020 Nov 12, 2020	SELL	$4.79 - $6.3 $7,185 - $9,450	-1,500 Reduced 14.3%	8,988 $43,000
Q2 2020 Aug 12, 2020	BUY	$4.5 - $6.53 $32,107 - $46,591	7,135 Added 212.79%	10,488 $64,000
Q1 2020 May 13, 2020	BUY	$5.25 - $9.9 $15,765 - $29,729	3,003 Added 858.0%	3,353 $18,000
Q4 2019 Feb 10, 2020	SELL	$5.84 - $10.51 $11,312 - $20,357	-1,937 Reduced 84.7%	350 $4,000
Q3 2019 Nov 14, 2019	BUY	$5.76 - $9.44 $1,175 - $1,925	204 Added 9.79%	2,287 $12,000
Q2 2019 Aug 14, 2019	SELL	$9.1 - $15.55 $139,867 - $239,003	-15,370 Reduced 88.07%	2,083 $18,000
Q1 2019 May 15, 2019	BUY	$12.5 - $18.48 $177,962 - $263,099	14,237 Added 442.69%	17,453 $243,000
Q4 2018 Feb 14, 2019	BUY	$15.25 - $22.4 $49,044 - $72,038	3,216 New	3,216 $51,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.